Innovation
Innovation
Improving Health for All
We develop new ways to promote faster development of valuable treatments and ensure diverse patient groups can access them.
Featured White Paper
The Elasticity of Pharmaceutical Innovation: How Much Does Revenue Drive New Drug Development?
For every 10% reduction in expected revenues, we can expect 2.5% to 15% less pharmaceutical innovation. Policymakers should take care to balance reductions in health outcomes long-term with short-term access improvements.
Experts: Karen Van Nuys, Darius Lakdawalla, Dana Goldman
Top Innovation Stories View All
Testimony
Testimony on Maintaining U.S. Biotech Competitiveness and Delivering Lifesaving Cures to Patients
In The News View All
KFF Health News
FDA’s shift away from independent drug reviews could shield the agency from scrutiny, Kanter says
Featured Experts: Genevieve P. Kanter
STAT
FDA staff cuts may undermine agency promises on “radical transparency” and fewer conflicts of interest, Kanter explains
Featured Experts: Genevieve P. Kanter
Barron's
Grogan quoted on the competitive threat the U.S. faces from Chinese biotech
Featured Experts: Joseph Grogan
Reuters
Padula provides insight on how rare disease therapies are influencing new drug pricing trends
Featured Experts: William Padula
POLITICO
“Most Favored Nation” could incentivize drugmakers to pull products overseas, hurting patients worldwide, Lakdawalla warns
Featured Experts: Darius Lakdawalla
Related Subtopics
High drug prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. We connect industry, academia and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Team View All Innovation Experts
